Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty

Kardiologia Polska

Volumn 71, Issue 5, 2013, Pages 453-463

  Kuliczkowski, Wiktor ^a   Urbaniak, Joanna ^b   Hallén, Jonas ^c   Woźniak, Mieczysław ^b   Poloński, Lech ^a   Mysiak, Andrzej ^b   Atar, Dan ^c   Zembala, Marian ^a   Serebruany, Victor ^d  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myocardial infarction; Matrix metalloproteinases (MMP); Primary PCI; Tissue inhibitors of MMP

Indexed keywords

CREATINE KINASE MB; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TROPONIN I;

ADULT; AGE DISTRIBUTION; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; TREATMENT OUTCOME; ZYMOGRAPHY;

EID: 84878911543     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.2013.0091     Document Type: Article

References (20)

1. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des, 2007; 13: 333-346.
2. Phatharajaree W, Phrommintikul A, Chattipakorn N. Matrix metalloproteinases and myocardial infarction. Can J Cardiol, 2007; 23: 727-733.
3. Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res, 2008; 121: 535-542.
4. Beaudeux JL, Giral P, Bruckert E et al. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med, 2004; 42: 121-131.
5. Ducharme A, Frantz S, Aikawa M et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest, 2000; 106: 55-62.
6. Hayashidani S, Tsutsui H, Ikeuchi M et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol, 2003; 285: H1229-H1235.
7. Mukherjee R, Brinsa TA, Dowdy KB et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation, 2003; 107: 618-625.
8. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem, 1994; 218: 325-329.
9. Wagner DR, Delagardelle C, Ernens I et al. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail, 2006; 12: 66-72.
10. Fukuda D, Shimada K, Tanaka A et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol, 2006; 97: 175-180.
11. Fiotti N, Altamura N, Orlando C et al. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int J Cardiol, 2008; 127: 350-357.
12. Inokubo Y, Hanada H, Ishizaka H et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J, 2001; 141: 211-217.
13. Chen F, Eriksson P, Hansson GK et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med, 2005; 15: 57-65.
14. Kelly D, Cockerill G, Ng LL et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J, 2007; 28: 711-718.
15. Eckart RE, Uyehara CF, Shry EA et al. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Interv Cardiol, 2004; 17: 27-31.
16. Tziakas DN, Chalikias GK, Parissis JT et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol, 2004; 94: 269-277.
17. Webb CS, Bonnema DD, Ahmed SH et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation, 2006; 114: 1020-1027.
18. Squire IB, Evans J, Ng LL et al. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail, 2004; 10: 328-333.
19. Matsunaga T, Abe N, Kameda K et al. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int J Cardiol, 2005; 105: 203-208.
20. Szulik M, Stabryla-Deska J, Boidol J et al. Echocardiography-based qualification and response assessment to cardiac resynchronisation therapy in patients with chronic heart failure. The matrix metalloproteinase-9 substudy. Kardiol Pol, 2011; 69: 1043-1051.